Selected research
Market Outlook & Growth Opportunities
Global Viral Gene Therapy Market Outlook and Growth Opportunities 2026
Market perspective
The global Viral Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Viral Gene Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Viral Gene Therapy market include AnGes, Catalent, Ionis Pharmaceuticals, Orchard Therapeutics, Sarepta Therapeutics, SIBIONO, Spark Therapeutics, Amgen and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Viral Gene Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Viral Gene Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Viral Gene Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Viral Gene Therapy market.
Viral Gene Therapy Segment by Company
AnGes
Catalent
Ionis Pharmaceuticals
Orchard Therapeutics
Sarepta Therapeutics
SIBIONO
Spark Therapeutics
Amgen
Biogen
Gilead Sciences
Lonza
Novartis
Shanghai Sunway Biotech
Viral Gene Therapy Segment by Type
Integrating Viral Vectors
Non-Integrating Viral Vectors
Viral Gene Therapy Segment by Application
Ophthalmologic Diseases
Hematologic Diseases
Cardiovascular Diseases
Muscular Diseases
Metabolic Diseases
Infectious Diseases
Others
Viral Gene Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Viral Gene Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Viral Gene Therapy key companies, revenue, market share, and recent developments.
3. To split the Viral Gene Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Viral Gene Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Viral Gene Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Viral Gene Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Gene Therapy industry.
Chapter 3: Detailed analysis of Viral Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Viral Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Viral Gene Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Viral Gene Therapy Industry Trends
Table 2. Viral Gene Therapy Industry Drivers
Table 3. Viral Gene Therapy Industry Opportunities and Challenges
Table 4. Viral Gene Therapy Industry Restraints
Table 5. Global Viral Gene Therapy Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Viral Gene Therapy Revenue Share by Company (2021-2026)
Table 7. Global Viral Gene Therapy Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Viral Gene Therapy Key Company Manufacturing Base & Headquarters
Table 9. Global Viral Gene Therapy Company, Product Type & Application
Table 10. Global Viral Gene Therapy Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Viral Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Integrating Viral Vectors
Table 15. Significant Companies of Non-Integrating Viral Vectors
Table 16. Global Viral Gene Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 17. Global Viral Gene Therapy Sales Value by Type (2021-2026) & (US$ Million)
Table 18. Global Viral Gene Therapy Sales Value by Type (2027-2032) & (US$ Million)
Table 19. Global Viral Gene Therapy Sales Value Share by Type (2021-2026)
Table 20. Global Viral Gene Therapy Sales Value Share by Type (2027-2032)
Table 21. Significant Companies of Ophthalmologic Diseases
Table 22. Significant Companies of Hematologic Diseases
Table 23. Significant Companies of Cardiovascular Diseases
Table 24. Significant Companies of Muscular Diseases
Table 25. Significant Companies of Metabolic Diseases
Table 26. Significant Companies of Infectious Diseases
Table 27. Significant Companies of Others
Table 28. Global Viral Gene Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 29. Global Viral Gene Therapy Sales Value by Application (2021-2026) & (US$ Million)
Table 30. Global Viral Gene Therapy Sales Value by Application (2027-2032) & (US$ Million)
Table 31. Global Viral Gene Therapy Sales Value Share by Application (2021-2026)
Table 32. Global Viral Gene Therapy Sales Value Share by Application (2027-2032)
Table 33. Global Viral Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Global Viral Gene Therapy Sales Value by Region (2021-2026) & (US$ Million)
Table 35. Global Viral Gene Therapy Sales Value Share by Region (2021-2026)
Table 36. Global Viral Gene Therapy Sales Value by Region (2027-2032) & (US$ Million)
Table 37. Global Viral Gene Therapy Sales Value Share by Region (2027-2032)
Table 38. Global Viral Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 39. Global Viral Gene Therapy Sales Value by Country (2021-2026) & (US$ Million)
Table 40. Global Viral Gene Therapy Sales Value Market Share by Country (2021-2026)
Table 41. Global Viral Gene Therapy Sales Value by Country (2027-2032) & (US$ Million)
Table 42. Global Viral Gene Therapy Sales Value Market Share by Country (2027-2032)
Table 43. AnGes Company Information
Table 44. AnGes Business Overview
Table 45. AnGes Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 46. AnGes Viral Gene Therapy Product Portfolio
Table 47. AnGes Recent Development
Table 48. Catalent Company Information
Table 49. Catalent Business Overview
Table 50. Catalent Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 51. Catalent Viral Gene Therapy Product Portfolio
Table 52. Catalent Recent Development
Table 53. Ionis Pharmaceuticals Company Information
Table 54. Ionis Pharmaceuticals Business Overview
Table 55. Ionis Pharmaceuticals Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 56. Ionis Pharmaceuticals Viral Gene Therapy Product Portfolio
Table 57. Ionis Pharmaceuticals Recent Development
Table 58. Orchard Therapeutics Company Information
Table 59. Orchard Therapeutics Business Overview
Table 60. Orchard Therapeutics Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 61. Orchard Therapeutics Viral Gene Therapy Product Portfolio
Table 62. Orchard Therapeutics Recent Development
Table 63. Sarepta Therapeutics Company Information
Table 64. Sarepta Therapeutics Business Overview
Table 65. Sarepta Therapeutics Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 66. Sarepta Therapeutics Viral Gene Therapy Product Portfolio
Table 67. Sarepta Therapeutics Recent Development
Table 68. SIBIONO Company Information
Table 69. SIBIONO Business Overview
Table 70. SIBIONO Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. SIBIONO Viral Gene Therapy Product Portfolio
Table 72. SIBIONO Recent Development
Table 73. Spark Therapeutics Company Information
Table 74. Spark Therapeutics Business Overview
Table 75. Spark Therapeutics Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 76. Spark Therapeutics Viral Gene Therapy Product Portfolio
Table 77. Spark Therapeutics Recent Development
Table 78. Amgen Company Information
Table 79. Amgen Business Overview
Table 80. Amgen Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 81. Amgen Viral Gene Therapy Product Portfolio
Table 82. Amgen Recent Development
Table 83. Biogen Company Information
Table 84. Biogen Business Overview
Table 85. Biogen Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 86. Biogen Viral Gene Therapy Product Portfolio
Table 87. Biogen Recent Development
Table 88. Gilead Sciences Company Information
Table 89. Gilead Sciences Business Overview
Table 90. Gilead Sciences Viral Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 91. Gilead Sciences Viral Gene Therapy Product Portfolio
Table 92. Gilead Sciences Recent Development
Table 93. Lonza Company Information
Table 94. Lonza Business Overview
Table 95. Lonza Viral Gene Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Lonza Viral Gene Therapy Product Portfolio
Table 97. Lonza Recent Development
Table 98. Novartis Company Information
Table 99. Novartis Business Overview
Table 100. Novartis Viral Gene Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Novartis Viral Gene Therapy Product Portfolio
Table 102. Novartis Recent Development
Table 103. Shanghai Sunway Biotech Company Information
Table 104. Shanghai Sunway Biotech Business Overview
Table 105. Shanghai Sunway Biotech Viral Gene Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Shanghai Sunway Biotech Viral Gene Therapy Product Portfolio
Table 107. Shanghai Sunway Biotech Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Authors List of This Report
Table 110. Secondary Sources
Table 111. Primary Sources
List of Figures
Figure 1. Viral Gene Therapy Product Image
Figure 2. Global Viral Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Viral Gene Therapy Market Size (2021-2032) & (US$ Million)
Figure 4. Global Viral Gene Therapy Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Integrating Viral Vectors Image
Figure 8. Non-Integrating Viral Vectors Image
Figure 9. Global Viral Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Viral Gene Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 11. Global Viral Gene Therapy Sales Value Share by Type (2021-2032)
Figure 12. Ophthalmologic Diseases Image
Figure 13. Hematologic Diseases Image
Figure 14. Cardiovascular Diseases Image
Figure 15. Muscular Diseases Image
Figure 16. Metabolic Diseases Image
Figure 17. Infectious Diseases Image
Figure 18. Others Image
Figure 19. Global Viral Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 20. Global Viral Gene Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 21. Global Viral Gene Therapy Sales Value Share by Application (2021-2032)
Figure 22. Global Viral Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 23. Global Viral Gene Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 24. North America Viral Gene Therapy Sales Value (2021-2032) & (US$ Million)
Figure 25. North America Viral Gene Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 26. Europe Viral Gene Therapy Sales Value (2021-2032) & (US$ Million)
Figure 27. Europe Viral Gene Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 28. Asia-Pacific Viral Gene Therapy Sales Value (2021-2032) & (US$ Million)
Figure 29. Asia-Pacific Viral Gene Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 30. South America Viral Gene Therapy Sales Value (2021-2032) & (US$ Million)
Figure 31. South America Viral Gene Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 32. Middle East & Africa Viral Gene Therapy Sales Value (2021-2032) & (US$ Million)
Figure 33. Middle East & Africa Viral Gene Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 34. USA Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 35. USA Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 36. USA Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 37. Canada Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 38. Canada Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 39. Canada Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 40. Mexico Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 41. Mexico Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 42. Mexico Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 43. Germany Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 44. Germany Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 45. Germany Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 46. France Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 47. France Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 48. France Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 49. U.K. Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 50. U.K. Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 51. U.K. Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 52. Italy Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 53. Italy Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 54. Italy Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 55. Spain Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 56. Spain Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 57. Spain Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 58. Russia Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 59. Russia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 60. Russia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 61. Netherlands Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 62. Netherlands Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 63. Netherlands Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 64. Nordic Countries Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 65. Nordic Countries Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 66. Nordic Countries Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 67. China Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 68. China Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 69. China Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 70. Japan Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 71. Japan Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 72. Japan Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 73. South Korea Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 74. South Korea Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 75. South Korea Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 76. India Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 77. India Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 78. India Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 79. Australia Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 80. Australia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 81. Australia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 82. Southeast Asia Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 83. Southeast Asia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 84. Southeast Asia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 85. Brazil Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 86. Brazil Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 87. Brazil Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 88. Argentina Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 89. Argentina Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 90. Argentina Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 91. Chile Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 92. Chile Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 93. Chile Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 94. Colombia Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 95. Colombia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 96. Colombia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 97. Peru Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 98. Peru Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 99. Peru Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 100. Saudi Arabia Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 101. Saudi Arabia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 102. Saudi Arabia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 103. Israel Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 104. Israel Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 105. Israel Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 106. UAE Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 107. UAE Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 108. UAE Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 109. Turkey Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 110. Turkey Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 111. Turkey Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 112. Iran Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 113. Iran Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 114. Iran Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 115. Egypt Viral Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 116. Egypt Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 117. Egypt Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 118. Years Considered
Figure 119. Research Process
Figure 120. Key Executives Interviewed
Scope & coverage.
Types
- Integrating Viral Vectors
- Non-Integrating Viral Vectors
Applications
- Ophthalmologic Diseases
- Hematologic Diseases
- Cardiovascular Diseases
- Muscular Diseases
- Metabolic Diseases
- Infectious Diseases
- Others
Companies covered
- AnGes
- Catalent
- Ionis Pharmaceuticals
- Orchard Therapeutics
- Sarepta Therapeutics
- SIBIONO
- Spark Therapeutics
- Amgen
- Biogen
- Gilead Sciences
- Lonza
- Novartis
- Shanghai Sunway Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Viral Gene Therapy Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Viral Gene Therapy Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Viral Gene Therapy Market Dynamics
- 2.1 Viral Gene Therapy Industry Trends
- 2.2 Viral Gene Therapy Industry Drivers
- 2.3 Viral Gene Therapy Industry Opportunities and Challenges
- 2.4 Viral Gene Therapy Industry Restraints
3 Viral Gene Therapy Market by Company
- 3.1 Global Viral Gene Therapy Company Revenue Ranking in 2025
- 3.2 Global Viral Gene Therapy Revenue by Company (2021-2026)
- 3.3 Global Viral Gene Therapy Company Ranking (2024-2026)
- 3.4 Global Viral Gene Therapy Company Manufacturing Base and Headquarters
- 3.5 Global Viral Gene Therapy Company Product Type and Application
- 3.6 Global Viral Gene Therapy Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Viral Gene Therapy Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Viral Gene Therapy Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Viral Gene Therapy Market by Type
- 4.1 Viral Gene Therapy Type Introduction
- 4.1.1 Integrating Viral Vectors
- 4.1.2 Non-Integrating Viral Vectors
- 4.2 Global Viral Gene Therapy Sales Value by Type
- 4.2.1 Global Viral Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Viral Gene Therapy Sales Value by Type (2021-2032)
- 4.2.3 Global Viral Gene Therapy Sales Value Share by Type (2021-2032)
5 Viral Gene Therapy Market by Application
- 5.1 Viral Gene Therapy Application Introduction
- 5.1.1 Ophthalmologic Diseases
- 5.1.2 Hematologic Diseases
- 5.1.3 Cardiovascular Diseases
- 5.1.4 Muscular Diseases
- 5.1.5 Metabolic Diseases
- 5.1.6 Infectious Diseases
- 5.1.7 Others
- 5.2 Global Viral Gene Therapy Sales Value by Application
- 5.2.1 Global Viral Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Viral Gene Therapy Sales Value by Application (2021-2032)
- 5.2.3 Global Viral Gene Therapy Sales Value Share by Application (2021-2032)
6 Viral Gene Therapy Regional Value Analysis
- 6.1 Global Viral Gene Therapy Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Viral Gene Therapy Sales Value by Region (2021-2032)
- 6.2.1 Global Viral Gene Therapy Sales Value by Region: 2021-2026
- 6.2.2 Global Viral Gene Therapy Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Viral Gene Therapy Sales Value (2021-2032)
- 6.3.2 North America Viral Gene Therapy Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Viral Gene Therapy Sales Value (2021-2032)
- 6.4.2 Europe Viral Gene Therapy Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Viral Gene Therapy Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Viral Gene Therapy Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Viral Gene Therapy Sales Value (2021-2032)
- 6.6.2 South America Viral Gene Therapy Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Viral Gene Therapy Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Viral Gene Therapy Sales Value Share by Country, 2025 VS 2032
7 Viral Gene Therapy Country-level Value Analysis
- 7.1 Global Viral Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Viral Gene Therapy Sales Value by Country (2021-2032)
- 7.2.1 Global Viral Gene Therapy Sales Value by Country (2021-2026)
- 7.2.2 Global Viral Gene Therapy Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.7.2 France Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.14.2 China Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.17.2 India Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Viral Gene Therapy Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Viral Gene Therapy Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Viral Gene Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 AnGes
- 8.1.1 AnGes Company Information
- 8.1.2 AnGes Business Overview
- 8.1.3 AnGes Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.1.4 AnGes Viral Gene Therapy Product Portfolio
- 8.1.5 AnGes Recent Developments
- 8.2 Catalent
- 8.2.1 Catalent Company Information
- 8.2.2 Catalent Business Overview
- 8.2.3 Catalent Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.2.4 Catalent Viral Gene Therapy Product Portfolio
- 8.2.5 Catalent Recent Developments
- 8.3 Ionis Pharmaceuticals
- 8.3.1 Ionis Pharmaceuticals Company Information
- 8.3.2 Ionis Pharmaceuticals Business Overview
- 8.3.3 Ionis Pharmaceuticals Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.3.4 Ionis Pharmaceuticals Viral Gene Therapy Product Portfolio
- 8.3.5 Ionis Pharmaceuticals Recent Developments
- 8.4 Orchard Therapeutics
- 8.4.1 Orchard Therapeutics Company Information
- 8.4.2 Orchard Therapeutics Business Overview
- 8.4.3 Orchard Therapeutics Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.4.4 Orchard Therapeutics Viral Gene Therapy Product Portfolio
- 8.4.5 Orchard Therapeutics Recent Developments
- 8.5 Sarepta Therapeutics
- 8.5.1 Sarepta Therapeutics Company Information
- 8.5.2 Sarepta Therapeutics Business Overview
- 8.5.3 Sarepta Therapeutics Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.5.4 Sarepta Therapeutics Viral Gene Therapy Product Portfolio
- 8.5.5 Sarepta Therapeutics Recent Developments
- 8.6 SIBIONO
- 8.6.1 SIBIONO Company Information
- 8.6.2 SIBIONO Business Overview
- 8.6.3 SIBIONO Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.6.4 SIBIONO Viral Gene Therapy Product Portfolio
- 8.6.5 SIBIONO Recent Developments
- 8.7 Spark Therapeutics
- 8.7.1 Spark Therapeutics Company Information
- 8.7.2 Spark Therapeutics Business Overview
- 8.7.3 Spark Therapeutics Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.7.4 Spark Therapeutics Viral Gene Therapy Product Portfolio
- 8.7.5 Spark Therapeutics Recent Developments
- 8.8 Amgen
- 8.8.1 Amgen Company Information
- 8.8.2 Amgen Business Overview
- 8.8.3 Amgen Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.8.4 Amgen Viral Gene Therapy Product Portfolio
- 8.8.5 Amgen Recent Developments
- 8.9 Biogen
- 8.9.1 Biogen Company Information
- 8.9.2 Biogen Business Overview
- 8.9.3 Biogen Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.9.4 Biogen Viral Gene Therapy Product Portfolio
- 8.9.5 Biogen Recent Developments
- 8.10 Gilead Sciences
- 8.10.1 Gilead Sciences Company Information
- 8.10.2 Gilead Sciences Business Overview
- 8.10.3 Gilead Sciences Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.10.4 Gilead Sciences Viral Gene Therapy Product Portfolio
- 8.10.5 Gilead Sciences Recent Developments
- 8.11 Lonza
- 8.11.1 Lonza Company Information
- 8.11.2 Lonza Business Overview
- 8.11.3 Lonza Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.11.4 Lonza Viral Gene Therapy Product Portfolio
- 8.11.5 Lonza Recent Developments
- 8.12 Novartis
- 8.12.1 Novartis Company Information
- 8.12.2 Novartis Business Overview
- 8.12.3 Novartis Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.12.4 Novartis Viral Gene Therapy Product Portfolio
- 8.12.5 Novartis Recent Developments
- 8.13 Shanghai Sunway Biotech
- 8.13.1 Shanghai Sunway Biotech Company Information
- 8.13.2 Shanghai Sunway Biotech Business Overview
- 8.13.3 Shanghai Sunway Biotech Viral Gene Therapy Revenue and Gross Margin (2021-2026)
- 8.13.4 Shanghai Sunway Biotech Viral Gene Therapy Product Portfolio
- 8.13.5 Shanghai Sunway Biotech Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst